Titlebook: Bone Drugs in Pediatrics; Efficacy and Challen Gordon L. Klein Book 2014 Springer Science+Business Media New York 2014 Anti-resorptive.Bisp

左右连贯

Introduction,revent or treat pediatric bone loss. Even though no drugs have current approval for this purpose from the United States Food and Drug Administration (FDA), these chapters contain evidence of both safety and efficacy of antiresorptive and anabolic medications that have been used off-label in a variety of pediatric conditions.

呼吸

Developmental Pharmacokinetics: Drug Disposition Relative to Age,ge-appropriate dose for a drug is dependent on its pharmacokinetic profile which is markedly influenced by the normal developmental changes that occur in body water compartments and cellular and organ function. This chapter reviews the influence of patient age on drug pharmacokinetics in pediatrics.

mediocrity

Deadpan

Use of Bisphosphonates in Genetic Diseases Other than Osteogenesis Imperfecta,to increase bone mass, reduce the risk of fractures, alleviate bone pain, and even, in some measure, hinder the formation of heterotopic bone. Only for the more common diseases, like Duchenne muscular dystrophy and cystic fibrosis, there are sufficient data to recommend the prudent use of BPs as a standard treatment of bone complications.

圣人

https://doi.org/10.1007/978-3-662-12290-7This chapter highlights the underlying physiological basis for these difficulties and describes the modalities used for monitoring the efficacy and safety of skeletal pharmacology in paediatric patients.

Gleason-score

Astronomy and Astrophysics Abstractsvent the acute post-burn bone loss but also permit continued new bone mass accretion with time. The lack of side effects suggests that this drug can be used both safely and effectively in pediatric burn patients to prevent bone loss and the manner of its successful use may have applications to other pediatric conditions, which will be discussed.

Heterodoxy

漂浮

Paediatric Bone Physiology and Monitoring the Safety and Efficacy of Bone Drugs in Children,This chapter highlights the underlying physiological basis for these difficulties and describes the modalities used for monitoring the efficacy and safety of skeletal pharmacology in paediatric patients.

急性

Bisphosphonates in Pediatric Burn Injury,vent the acute post-burn bone loss but also permit continued new bone mass accretion with time. The lack of side effects suggests that this drug can be used both safely and effectively in pediatric burn patients to prevent bone loss and the manner of its successful use may have applications to other pediatric conditions, which will be discussed.

合并

Pediatric Bone Drugs: Calcium and Vitamin D,he sources and metabolism of calcium and vitamin D, the mechanism of their effect on bone, the significant pediatric studies that have shaped our understanding of this topic, and current recommendations guiding our use of calcium and vitamin D as pediatric bone drugs.